1. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
    Athanasios Kotsakis et al, 2016, Sci Rep CrossRef
  2. Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer
    Qiu-Zhong Pan et al, 2015, OncoImmunology CrossRef
  3. Expression of GARP Is Increased in Tumor-Infiltrating Regulatory T Cells and Is Correlated to Clinicopathology of Lung Cancer Patients
    Hao Jin et al, 2017, Front. Immunol. CrossRef
  4. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment
    Mao Lin et al, 2017, J Cancer Res Clin Oncol CrossRef
  5. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer
    Mao Lin et al, 2017, Immunology Letters CrossRef
  6. Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer
    Lingyan Wang et al, 2017, Seminars in Cell & Developmental Biology CrossRef
  7. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer
    Mao Lin et al, 2017, Immunology Letters CrossRef
  8. null
    Anthony R. Cillo et al, 2018 CrossRef
  9. Clinical significance of expanded Foxp3+ Helios− regulatory T cells in patients with non-small cell lung cancer
    SATOSHI MUTO et al, 2015 CrossRef
  10. Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs
    Yasuteru Kondo et al, 2015, IJMS CrossRef
  11. Increased regulatory T cells in acute lymphoblastic leukemia patients
    Siti-Zuleha Idris et al, 2015, Hematology CrossRef
  12. Increased regulatory T cells in acute lymphoblastic leukaemia patients
    Siti-Zuleha Idris et al, 2016, Hematology CrossRef
  13. Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma
    Morimichi Nishihira et al, 2018, Thorac Cancer CrossRef
  14. Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer
    Nathalie Chaput et al, 2015, Eur Respir J CrossRef
  15. null
    Jiang He et al, 2019 CrossRef
  16. FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma
    Alexandra Giatromanolaki et al, 2019, Experimental Lung Research CrossRef
  17. Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
    Ding Zhang et al, 2015, Cancer Metastasis Rev CrossRef
  18. CD8highCD57+ T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer
    Neringa T. Dobrovolskienė et al, 2015, Lung Cancer CrossRef
  19. Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg
    Sebastian Dietmar Barth et al, 2015, JNCI.J CrossRef
  20. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
    Fan Yan et al, 2015, Cancer Immunol Immunother CrossRef
  21. The prognostic influence of tumor infiltrating Foxp3+CD4+, CD4+ and CD8+ T cells in resected non-small cell lung cancer
    Jurgita Jackute et al, 2015, J Inflamm CrossRef
  22. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.
    Philipp Müller et al, 2016, Cancer Immunol. Immunother. CrossRef
  23. PLGA-Der p1 Vaccine Inhibited Tumor Growth in a Murine Model of Lung Cancer
    Jianhong Zuo et al, 2015, Archives of Medical Research CrossRef
  24. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
    Yang Wang et al, 2019, Eur J Nucl Med Mol Imaging CrossRef
  25. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer
    Mao Lin et al, 2017, Immunology Letters CrossRef
  26. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer
    Mao Lin et al, 2017, Immunol Res CrossRef
  27. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer
    Mao Lin et al, 2017, Oncotarget CrossRef
  28. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
    Dong-Qiang Zeng et al, 2016, Oncotarget CrossRef
  29. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer
    Mao Lin et al, 2017, Oncotarget CrossRef
  30. Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal
    Wojciech Jóźwicki et al, 2016, Oncotarget CrossRef
  31. Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis
    Benchao Chen et al, 2020, PLoS ONE CrossRef
  32. Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas
    Mona Mlika et al, 2021, Asian Cardiovasc Thorac Ann CrossRef
  33. Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer
    Bing Yan et al, 2022, BMC Gastroenterol CrossRef
  34. Circulating T regulatory cell subsets in patients with untreated lung cancer
    Dahiana Amarillo et al, 2022, Clin Transl Oncol CrossRef
  35. Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect
    Xiang Li et al, 2022, ACS Appl. Mater. Interfaces CrossRef
  36. Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients
    Denisa Baci et al, 2022, Front. Immunol. CrossRef